Analysts Have Conflicting Sentiments on These Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), Vor Biopharma (VOR) and Organogenesis Holdings (ORGO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Andlauer Healthcare Group (ANDHF – Research Report), Vor Biopharma (VOR – Research Report) and Organogenesis Holdings (ORGO – Research Report).

Andlauer Healthcare Group (ANDHF)

RBC Capital analyst Walter Spracklin maintained a Hold rating on Andlauer Healthcare Group today and set a price target of C$46.00. The company’s shares closed last Friday at $37.80, close to its 52-week low of $37.64.

According to TipRanks.com, Spracklin is a top 100 analyst with an average return of 16.7% and a 65.1% success rate. Spracklin covers the Industrial Goods sector, focusing on stocks such as Canadian National Railway, Waste Connections, and GFL Environmental.

Currently, the analyst consensus on Andlauer Healthcare Group is a Moderate Buy with an average price target of $40.13.

See Insiders’ Hot Stocks on TipRanks >>

Vor Biopharma (VOR)

In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Vor Biopharma, with a price target of $18.00. The company’s shares closed last Friday at $5.03.

According to TipRanks.com, Walsh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.4% and a 33.3% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Fusion Pharmaceuticals, and POINT Biopharma Global.

Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $16.44.

Organogenesis Holdings (ORGO)

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Organogenesis Holdings, with a price target of $10.00. The company’s shares closed last Friday at $4.03.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 11.4% and a 48.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Treace Medical Concepts, and Zimmer Biomet Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Organogenesis Holdings with a $10.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.